Nanobiotix S.A. (5NR)
Munich
Closed
Aug 24, 2026
Day's Range
37.6252 wk Range
7.29Overview - 5NR - Nanobiotix S.A.
Key Statistics
Valuation
Enterprise Value
42.56M
EV / EBITDA
‪-4.81‬
Profitability
Operating Margin
‪-45.75%‬
Return on Assets
‪-35.36%‬
Return on Equity
‪28.36%‬
Ownership
Shares Outstanding
48.38M
Price stats
50-Day Avg
‪33.35‬
200-Day Avg
‪26.95‬
Peers - 5NR - Nanobiotix S.A.
Peer Comparison
Compared with companies in Biotechnology listed on Munich.
- 5NRMunichNanobiotix S.A.+77.80%52-week change—P/E (Trailing)—Profit Margin
- 0QFMunichModerna, Inc.+81.73%52-week change25.19P/E (Trailing)‪-141.42%‬Profit Margin
- 4E2MunichRelmada Therapeutics Inc.+86.82%52-week change-2.80P/E (Trailing)—Profit Margin
- 42ZMunichRevolution Medicines Inc.+82.82%52-week change-30.32P/E (Trailing)—Profit Margin
- 5JA1MunichSprint Bioscience AB+82.07%52-week change0.28P/E (Trailing)‪92.17%‬Profit Margin
- B9B9P0MunichNovabay Pharmaceuticals Inc. R+80.00%52-week change-0.01P/E (Trailing)—Profit Margin
- 87EMunichDianthus Therapeutics Inc.+78.62%52-week change-22.50P/E (Trailing)—Profit Margin
Profile Summary - 5NR - Nanobiotix S.A.
About
Nanobiotix S.A. is a late-stage clinical biotechnology company specializing in physics-based nanomedicines to revolutionize cancer treatment. Headquartered in Paris, France, with offices in the United States, it pioneers nanotechnology that enhances radiotherapy's efficacy. The company's lead candidate, NBTXR3…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
